This document is an excerpt from the EUR-Lex website
Document 52002XC0426(01)
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March to 15 April 2002 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March to 15 April 2002 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March to 15 April 2002 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)
IO C 101, 26.4.2002, p. 2–7
(ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March to 15 April 2002 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)
Official Journal C 101 , 26/04/2002 P. 0002 - 0007
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March to 15 April 2002 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93(1)) (2002/C 101/02) - Issuing of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted >TABLE> - Modification of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted >TABLE> - Withdrawal of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93) >TABLE> - Modification of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93: Accepted >TABLE> Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact: The European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom. (1) OJ L 214, 24.8.1993, p. 1.